© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
Daily Medication Pearl: Insulin Degludec Injection (Tresiba)
Tresiba is indicated to improve glycemic control in patients with diabetes.
Medication Pearl of the Day: Insulin degludec injection (Tresiba)
Indication: Tresiba is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus.
Insight:
- Dosing: Individualize dose based on type of diabetes, metabolic needs, blood glucose monitoring results, and glycemic control goal.
- Dosage forms: Tresiba is available in package sizes of 100 units/mL (U-100): 3 mL FlexTouch; 200 units/mL (U-200): 3 mL FlexTouch
- Adverse events: Hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, 56 pruritus, rash, edema, and weight gain.
- Mechanism of action: The primary activity of insulin, including Tresiba, is regulation of glucose metabolism.
- Manufacturer: Tresiba forms multi-hexamers when injected into the subcutaneous (SC) tissue resulting in a SC insulin degludec depot. The protracted time action profile of Tresiba is predominantly due to delayed absorption of insulin degludec from the SC tissue to the systemic circulation and, to a lesser extent, due to binding of insulin-degludec to circulating albumin.
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203314lbl.pdf
